Elevation Oncology, Inc.
DelistedCIK 1783032fmd_1F2Y01GJCE1DK0GJ0RS5SRQNMRManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2020 to Mar 31, 2025, 20 periods
Latest annual · FY2024
Millions- Operating income
- (45)
- Net income
- (44)
- Free cash flow
- (56)
Latest quarter · Q1 FY2025
Millions- Operating income
- (14)
- Net income
- (14)
Elevation Oncology, Inc. financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2024 | FY2023 | Change | Source |
|---|---|---|---|---|
| Operating income | -$44.7 million | -$45.4 million | 10-K 2025-03-06 · proof | |
| Net income | -$44.5 million | -$45.7 million | 10-K 2025-03-06 · proof | |
| Cash from operating activities | -$36.4 million | -$56.2 million | 10-K 2025-03-06 · proof | |
| Total assets | $95.6 million | $89.1 million | +7.3% | 10-K 2025-03-06 · proof |
| Total liabilities | $35.6 million | $34.3 million | +3.8% | 10-K 2025-03-06 · proof |
| Cash and cash equivalents | $49.5 million | $49.3 million | +0.4% | 10-K 2025-03-06 · proof |
- What was Elevation Oncology, Inc.'s operating income in fiscal 2024?
- Elevation Oncology, Inc. reported operating income of -$44.7 million for fiscal 2024 (the year ended Dec 31, 2024), against -$45.4 million the year before. Source: the 10-K filed with the SEC on Mar 6, 2025. SEC
- What was Elevation Oncology, Inc.'s net income in fiscal 2024?
- Elevation Oncology, Inc. reported net income of -$44.5 million for fiscal 2024 (the year ended Dec 31, 2024), against -$45.7 million the year before. Source: the 10-K filed with the SEC on Mar 6, 2025. SEC
- What was Elevation Oncology, Inc.'s cash from operating activities in fiscal 2024?
- Elevation Oncology, Inc. reported cash from operating activities of -$36.4 million for fiscal 2024 (the year ended Dec 31, 2024), against -$56.2 million the year before. Source: the 10-K filed with the SEC on Mar 6, 2025. SEC
- What are Elevation Oncology, Inc.'s total assets?
- As of Dec 31, 2024, Elevation Oncology, Inc. reported total assets of $95.6 million, against $89.1 million a year earlier (+7.3%). Source: the 10-K filed with the SEC on Mar 6, 2025. SEC
- What are Elevation Oncology, Inc.'s total liabilities?
- As of Dec 31, 2024, Elevation Oncology, Inc. reported total liabilities of $35.6 million, against $34.3 million a year earlier (+3.8%). Source: the 10-K filed with the SEC on Mar 6, 2025. SEC
- What are Elevation Oncology, Inc.'s cash and cash equivalents?
- As of Dec 31, 2024, Elevation Oncology, Inc. reported cash and cash equivalents of $49.5 million, against $49.3 million a year earlier (+0.4%). Source: the 10-K filed with the SEC on Mar 6, 2025. SEC
Read from the FinancialMD API on Nov 14, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:1783032&period_type=annual&limit=5"Information only, not investment advice.